Citius Pharmaceuticals, Inc. CTXR
We take great care to ensure that the data presented and summarized in this overview for Citius Pharmaceuticals, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding CTXR
View all-
Armistice Capital, LLC New York, NY7.28MShares$21.2 Million0.06% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.44MShares$18.7 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA1.88MShares$5.47 Million0.0% of portfolio
-
Black Rock Inc. New York, NY1.81MShares$5.25 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny1.16MShares$3.37 Million0.0% of portfolio
-
Advisor Group Holdings, Inc. Phoenix, AZ932KShares$2.71 Million0.0% of portfolio
-
Squarepoint Ops LLC New York, NY659KShares$1.92 Million0.0% of portfolio
-
State Street Corp Boston, MA582KShares$1.69 Million0.0% of portfolio
-
Northern Trust Corp Chicago, IL319KShares$929,3250.0% of portfolio
-
Chelsea Counsel CO281KShares$818,5830.07% of portfolio
Latest Institutional Activity in CTXR
Top Purchases
Top Sells
About CTXR
Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome; and I/ONTAK, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
Insider Transactions at CTXR
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Mar 13
2024
|
Eugene Myron Holuka Director |
SELL
Payment of exercise price or tax liability
|
Direct |
48
-1.99%
|
$0
$0.75 P/Share
|
Mar 13
2024
|
Eugene Myron Holuka Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,415
+50.0%
|
$0
$0.02 P/Share
|
Mar 04
2024
|
Carol Webb Director |
SELL
Payment of exercise price or tax liability
|
Direct |
236
-1.96%
|
$0
$0.77 P/Share
|
Mar 04
2024
|
Carol Webb Director |
BUY
Exercise of conversion of derivative security
|
Direct |
12,071
+50.0%
|
$0
$0.02 P/Share
|
Last 12 Months Summary
Exercise of conversion of derivative security | 14.5K shares |
---|
Payment of exercise price or tax liability | 284 shares |
---|